JNJ Johnson & Johnson

XNYS Up Alert

Health Care

· How we analyze

About the company

Johnson & Johnson is a healthcare company from New Jersey. It develops prescription drugs, for example for cancer and immune diseases, and makes medical devices such as implants, cardiac catheters and surgical equipment. The over-the-counter products division was separated as Kenvue. As of Oct 13, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · New Brunswick, USA

The group is a holding company whose companies research, manufacture and sell healthcare products in almost every country. The pharmaceutical segment covers oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include DARZALEX for multiple myeloma and ERLEADA for prostate cancer. The pharmaceuticals go directly to retailers, wholesalers, distributors, hospitals and healthcare professionals. The MedTech segment develops and manufactures products for cardiovascular, orthopedics, surgery and eye health, including systems from Abiomed and Shockwave.

Automatically summarized from SEC annual report (10-K, filed Feb 11, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +0.9%
  • 7 days +3.6%
  • 30 days −0.9%
  • 1 year +41.2%
Day range (last trading day)
−1.5%Price at 92% of the range+0.1%
52-week range
−31.3%Price at 87% of the range+4.6%
Distance from the all-time high
−4.4%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Pullback in trend · Analysis method

This method currently detects no pattern for JNJ. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? In an intact uptrend (price above the 200-day line, 50-day line rising), the price pulls back to the 50-day line after a rise and closes back above it.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:JNJ

Fundamental analysis

Johnson & Johnson · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 11, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 28, 2025

Quality Profitability, consistency, balance sheet · 1 without data 7 of 7 criteria met Growth Revenue and earnings per share · 1 without data 4 of 6 criteria met Dividend Level, consistency, coverage 7 of 7 criteria met Financial strength Piotroski, debt, liquidity 5 of 6 criteria met

Quality 7 of 7 met · 1 without data

  • met: Gross margin above 40% 67.9%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 28.5%
  • met: Return on equity above 15% 32.9%
  • met: Free cash flow margin above 10% 20.9%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 40.9%
Gross margin

67.9% Fiscal year 2025

Rank 76 of 100: higher than 76% of 153 peers (All). strong.

Rank 58 of 100: higher than 58% of 20 peers (Sector). medium.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Net margin

28.5% Fiscal year 2025

Rank 82 of 100: higher than 82% of 237 peers (All). strong.

Rank 79 of 100: higher than 79% of 26 peers (Sector). strong.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

32.9% Fiscal year 2025

Rank 76 of 100: higher than 76% of 218 peers (All). strong.

Rank 74 of 100: higher than 74% of 21 peers (Sector). strong.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

13.5% Fiscal year 2025 (total assets at year end)

Rank 80 of 100: higher than 80% of 238 peers (All). strong.

Rank 79 of 100: higher than 79% of 26 peers (Sector). strong.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

40.9% Fiscal year 2025

Rank 60 of 100: higher than 60% of 239 peers (All). medium.

Rank 56 of 100: higher than 56% of 26 peers (Sector). medium.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

20.9% Fiscal year 2025

Rank 71 of 100: higher than 71% of 213 peers (All). strong.

Rank 66 of 100: higher than 66% of 25 peers (Sector). medium.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

19.7B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 4 of 6 met · 1 without data

  • not met: Over 3 years, revenue grew by more than 5% per year −0.3%
  • not met: Over 5 years, revenue grew by more than 5% per year +2.7%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • met: Over 3 years, EPS grew by more than 5% per year +17.9%
  • met: Over 5 years, EPS grew by more than 5% per year +14.9%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +6.0%
Revenue growth 3 years

−0.3% per year

Rank 17 of 100: higher than 17% of 230 peers (All). weak.

Rank 22 of 100: higher than 22% of 25 peers (Sector). weak.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+2.7% per year

Rank 10 of 100: higher than 10% of 217 peers (All). weak.

Rank 10 of 100: higher than 10% of 25 peers (Sector). weak.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

EPS growth 3 years

+17.9% per year

Rank 63 of 100: higher than 63% of 157 peers (All). medium.

Rank 84 of 100: higher than 84% of 22 peers (Sector). strong.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+14.9% per year

Rank 54 of 100: higher than 54% of 146 peers (All). medium.

Rank 73 of 100: higher than 73% of 20 peers (Sector). strong.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+7.2% per year

Rank 36 of 100: higher than 36% of 140 peers (All). medium.

Rank 43 of 100: higher than 43% of 20 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 5.14 USD
  • met: Payout ratio at most 60% of earnings 47%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +5.2%
  • met: Free cash flow per share covers the dividend 1.6x
  • met: Dividends paid over the last 5 years covered by free cash flow 62% of free cash flow
Payout ratio

47% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+5.2% per year

Rank 23 of 100: higher than 23% of 118 peers (All). weak.

Rank 16 of 100: higher than 16% of 16 peers (Sector). weak.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

1.6x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 4 of 9
  • met: Long-term debt no higher than equity 0.48
  • met: Current assets cover current liabilities 1.03
  • met: Positive equity 81.5B USD
  • met: In 5 years, share count up by at most 5% −9.0%
  • met: Free cash flow positive in the last fiscal year 19.7B USD
Piotroski F-Score

4 of 9 Fiscal year 2025

Rank 8 of 100: higher than 8% of 134 peers (All). weak.

Rank 11 of 100: higher than 11% of 19 peers (Sector). weak.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.48 at fiscal year end

Rank 58 of 100: lower than 58% of 199 peers (All). medium.

Rank 75 of 100: lower than 75% of 18 peers (Sector). strong.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.03 at fiscal year end

Rank 26 of 100: higher than 26% of 215 peers (All). weak.

Rank 25 of 100: higher than 25% of 26 peers (Sector). weak.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−9.0% in 5 years

Rank 77 of 100: lower than 77% of 199 peers (All). strong.

Rank 77 of 100: lower than 77% of 24 peers (Sector). strong.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • not met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+2.7% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+12.7% per year), at least as fast as the sector median; per share +14.9% per year.
  • Light green: Net margin 28.5%, above the sector median (12.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 4, 2016 – Jan 1, 2017): Revenue 71.9B USD · Net income 16.5B USD · Net margin 23.0%
  2. Fiscal year 2017 (Jan 2, 2017 – Dec 31, 2017): Revenue 76.5B USD · Net income 1.3B USD · Net margin 1.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 30, 2018): Revenue 81.6B USD · Net income 15.3B USD · Net margin 18.8%
  4. Fiscal year 2019 (Dec 31, 2018 – Dec 29, 2019): Revenue 82.1B USD · Net income 15.1B USD · Net margin 18.4%
  5. Fiscal year 2020 (Dec 30, 2019 – Jan 3, 2021): Revenue 82.6B USD · Net income 14.7B USD · Net margin 17.8%
  6. Fiscal year 2021 (Jan 4, 2021 – Jan 2, 2022): Revenue 93.8B USD · Net income 20.9B USD · Net margin 22.3%
  7. Fiscal year 2022 (Jan 3, 2022 – Jan 1, 2023): Revenue 94.9B USD · Net income 17.9B USD · Net margin 18.9%
  8. Fiscal year 2023 (Jan 2, 2023 – Dec 31, 2023): Revenue 85.2B USD · Net income 35.2B USD · Net margin 41.3%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 29, 2024): Revenue 88.8B USD · Net income 14.1B USD · Net margin 15.8%
  10. Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 94.2B USD · Net income 26.8B USD · Net margin 28.5%

Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 94.2B USD · Net income 26.8B USD · Net margin 28.5%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 67.9 USD gross profit and 28.5 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue94.2B USD100.0%
Gross profit63.9B USD67.9%
Cost of revenue30.3B USD32.1%
Net income26.8B USD28.5%
Research & development14.7B USD15.6%
Interest expense971.0M USD1.0%
Taxes5.8B USD6.1%
Remaining costs & other15.7B USD16.7%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from 17.8% to 28.5%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 69.8% · Net margin 23.0%
  2. Fiscal year 2017: Gross margin 66.8% · Net margin 1.7%
  3. Fiscal year 2018: Gross margin 66.8% · Net margin 18.8%
  4. Fiscal year 2019: Gross margin 66.4% · Net margin 18.4%
  5. Fiscal year 2020: Gross margin 65.6% · Net margin 17.8%
  6. Fiscal year 2021: Gross margin 68.2% · Net margin 22.3%
  7. Fiscal year 2022: Gross margin 67.3% · Net margin 18.9%
  8. Fiscal year 2023: Gross margin 68.8% · Net margin 41.3%
  9. Fiscal year 2024: Gross margin 69.1% · Net margin 15.8%
  10. Fiscal year 2025: Gross margin 67.9% · Net margin 28.5%

Returns

Return on equity rose in 5 years from 23.3% to 32.9%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 23.5% · Return on assets 11.7%
  2. Fiscal year 2017: Return on equity 2.2% · Return on assets 0.8%
  3. Fiscal year 2018: Return on equity 25.6% · Return on assets 10.0%
  4. Fiscal year 2019: Return on equity 25.4% · Return on assets 9.6%
  5. Fiscal year 2020: Return on equity 23.3% · Return on assets 8.4%
  6. Fiscal year 2021: Return on equity 28.2% · Return on assets 11.5%
  7. Fiscal year 2022: Return on equity 23.4% · Return on assets 9.6%
  8. Fiscal year 2023: Return on equity 51.1% · Return on assets 21.0%
  9. Fiscal year 2024: Return on equity 19.7% · Return on assets 7.8%
  10. Fiscal year 2025: Return on equity 32.9% · Return on assets 13.5%

Equity and long-term debt

The equity ratio rose in 5 years from 36.2% to 40.9%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 70.4B USD · Long-term debt 22.4B USD
  2. Fiscal year 2017: Equity 60.2B USD · Long-term debt 30.7B USD
  3. Fiscal year 2018: Equity 59.8B USD · Long-term debt 27.7B USD
  4. Fiscal year 2019: Equity 59.5B USD · Long-term debt 26.5B USD
  5. Fiscal year 2020: Equity 63.3B USD · Long-term debt 32.6B USD
  6. Fiscal year 2021: Equity 74.0B USD · Long-term debt 30.0B USD
  7. Fiscal year 2022: Equity 76.8B USD · Long-term debt 26.9B USD
  8. Fiscal year 2023: Equity 68.8B USD · Long-term debt 25.9B USD
  9. Fiscal year 2024: Equity 71.5B USD · Long-term debt 30.7B USD
  10. Fiscal year 2025: Equity 81.5B USD · Long-term debt 39.4B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.21 to 1.03.

Current ratio
  1. Fiscal year 2016: Current ratio 2.47
  2. Fiscal year 2017: Current ratio 1.41
  3. Fiscal year 2018: Current ratio 1.47
  4. Fiscal year 2019: Current ratio 1.26
  5. Fiscal year 2020: Current ratio 1.21
  6. Fiscal year 2021: Current ratio 1.35
  7. Fiscal year 2022: Current ratio 0.99
  8. Fiscal year 2023: Current ratio 1.16
  9. Fiscal year 2024: Current ratio 1.11
  10. Fiscal year 2025: Current ratio 1.03

Cash flow

Free cash flow stayed roughly the same in 5 years (19.7B USD).

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 18.8B USD · Capital expenditure 3.2B USD · Free cash flow 15.5B USD
  2. Fiscal year 2017: Operating cash flow 21.1B USD · Capital expenditure 3.3B USD · Free cash flow 17.8B USD
  3. Fiscal year 2018: Operating cash flow 22.2B USD · Capital expenditure 3.7B USD · Free cash flow 18.5B USD
  4. Fiscal year 2019: Operating cash flow 23.4B USD · Capital expenditure 3.5B USD · Free cash flow 19.9B USD
  5. Fiscal year 2020: Operating cash flow 23.5B USD · Capital expenditure 3.3B USD · Free cash flow 20.2B USD
  6. Fiscal year 2021: Operating cash flow 23.4B USD · Capital expenditure 3.7B USD · Free cash flow 19.8B USD
  7. Fiscal year 2022: Operating cash flow 21.2B USD · Capital expenditure 4.0B USD · Free cash flow 17.2B USD
  8. Fiscal year 2023: Operating cash flow 22.8B USD · Capital expenditure 4.5B USD · Free cash flow 18.2B USD
  9. Fiscal year 2024: Operating cash flow 24.3B USD · Capital expenditure 4.4B USD · Free cash flow 19.8B USD
  10. Fiscal year 2025: Operating cash flow 24.5B USD · Capital expenditure 4.8B USD · Free cash flow 19.7B USD

Share count

The share count fell in 5 years by 9.0% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 2.8B
  2. Fiscal year 2017: Diluted share count 2.7B
  3. Fiscal year 2018: Diluted share count 2.7B
  4. Fiscal year 2019: Diluted share count 2.7B
  5. Fiscal year 2020: Diluted share count 2.7B
  6. Fiscal year 2021: Diluted share count 2.7B
  7. Fiscal year 2022: Diluted share count 2.7B
  8. Fiscal year 2023: Diluted share count 2.6B
  9. Fiscal year 2024: Diluted share count 2.4B
  10. Fiscal year 2025: Diluted share count 2.4B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
5.14 USD · Fiscal year 2025
Dividend growth per year
3 y +4.9%5 y +5.2%10 y +5.7%
Years without a cut
at least 10 as far as the data goes
Payout ratio
of earnings 47% of free cash flow 63%
To shareholders (5 years)
81.6B USD 28% through repurchases
Share count over 5 years
−9.0% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 3.98 USD to 5.14 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 3.15 USD
  2. Fiscal year 2017: Dividend per share 3.32 USD
  3. Fiscal year 2018: Dividend per share 3.54 USD
  4. Fiscal year 2019: Dividend per share 3.75 USD
  5. Fiscal year 2020: Dividend per share 3.98 USD
  6. Fiscal year 2021: Dividend per share 4.19 USD
  7. Fiscal year 2022: Dividend per share 4.45 USD
  8. Fiscal year 2023: Dividend per share 4.70 USD
  9. Fiscal year 2024: Dividend per share 4.91 USD
  10. Fiscal year 2025: Dividend per share 5.14 USD

Payout ratios

The payout ratio fell in 5 years from 72.2% to 46.6%.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2016: Payout ratio (earnings) 53.1% · Payout ratio (free cash flow) 55.5%
  2. Fiscal year 2017: Payout ratio (earnings) not available · Payout ratio (free cash flow) 50.3%
  3. Fiscal year 2018: Payout ratio (earnings) 63.1% · Payout ratio (free cash flow) 51.2%
  4. Fiscal year 2019: Payout ratio (earnings) 66.6% · Payout ratio (free cash flow) 49.8%
  5. Fiscal year 2020: Payout ratio (earnings) 72.2% · Payout ratio (free cash flow) 51.9%
  6. Fiscal year 2021: Payout ratio (earnings) 53.6% · Payout ratio (free cash flow) 55.8%
  7. Fiscal year 2022: Payout ratio (earnings) 66.1% · Payout ratio (free cash flow) 68.0%
  8. Fiscal year 2023: Payout ratio (earnings) 34.3% · Payout ratio (free cash flow) 64.5%
  9. Fiscal year 2024: Payout ratio (earnings) 84.8% · Payout ratio (free cash flow) 59.6%
  10. Fiscal year 2025: Payout ratio (earnings) 46.6% · Payout ratio (free cash flow) 62.9%

What goes back to shareholders

Over 5 years, 81.6B USD went back to shareholders, 28% of it through share repurchases. That is 86% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD Dividends partly reported as declared rather than paid.
  1. Fiscal year 2016: Dividends paid 8.6B USD · Share repurchases 9.0B USD · New shares issued (including employee plans) not available · Free cash flow 15.5B USD
  2. Fiscal year 2017: Dividends paid 8.9B USD · Share repurchases 6.4B USD · New shares issued (including employee plans) not available · Free cash flow 17.8B USD
  3. Fiscal year 2018: Dividends paid 9.5B USD · Share repurchases 5.9B USD · New shares issued (including employee plans) not available · Free cash flow 18.5B USD
  4. Fiscal year 2019: Dividends paid 9.9B USD · Share repurchases 6.7B USD · New shares issued (including employee plans) not available · Free cash flow 19.9B USD
  5. Fiscal year 2020: Dividends paid 10.5B USD · Share repurchases 3.2B USD · New shares issued (including employee plans) not available · Free cash flow 20.2B USD
  6. Fiscal year 2021: Dividends paid 11.0B USD · Share repurchases 3.5B USD · New shares issued (including employee plans) not available · Free cash flow 19.8B USD
  7. Fiscal year 2022: Dividends paid 11.7B USD · Share repurchases 6.0B USD · New shares issued (including employee plans) not available · Free cash flow 17.2B USD
  8. Fiscal year 2023: Dividends paid 11.8B USD · Share repurchases 5.1B USD · New shares issued (including employee plans) not available · Free cash flow 18.2B USD
  9. Fiscal year 2024: Dividends paid 11.8B USD · Share repurchases 2.4B USD · New shares issued (including employee plans) not available · Free cash flow 19.8B USD
  10. Fiscal year 2025: Dividends paid 12.4B USD · Share repurchases 6.0B USD · New shares issued (including employee plans) not available · Free cash flow 19.7B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Johnson & Johnson next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison JNJ, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
ELV Elevance Health 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
JNJ Johnson & Johnson this stock 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
PFE Pfizer 62.6B USD +8.5%74.3%–12.4%9.0%41.5%14.5%6/9
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+2.7% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 2.7% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+12.7% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +14.9% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 12.7% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

28.5% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 28.46 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 17.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.44 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.44 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

47% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.47 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
94.2B USD
Revenue vs. prior year
+6.0%
Net income (FY)
26.8B USD
Net income vs. prior year
+90.6%
EPS (FY)
11.03 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
–
Fiscal year to Dec 28, 2025 · 10-K filed Feb 11, 2026 · Balance sheet Sep 27, 2026 (filed Oct 21, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 28, 2025 94.2B26.8B 28.5% 11.03 5.14 47%
2024Dec 29, 2024 88.8B14.1B 15.8% 5.79 4.91 85%
2023Dec 31, 2023 85.2B35.2B 41.3% 13.72 4.70 34%
2022Jan 1, 2023 94.9B17.9B 18.9% 6.73 4.45 66%
2021Jan 2, 2022 93.8B20.9B 22.3% 7.81 4.19 54%
2020Jan 3, 2021 82.6B14.7B 17.8% 5.51 3.98 72%
2019Dec 29, 2019 82.1B15.1B 18.4% 5.63 3.75 67%
2018Dec 30, 2018 81.6B15.3B 18.8% 5.61 3.54 63%
2017Dec 31, 2017 76.5B1.3B 1.7% 0.47 3.32 706%
2016Jan 1, 2017 71.9B16.5B 23.0% 5.93 3.15 53%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 27, 2026 25.4B210.0M 0.8% 0.09 1.34 1,489%
Q2/26Jun 28, 2026 25.3B5.5B 21.9% 2.27 1.34 59%
Q1/26Mar 29, 2026 24.1B5.2B 21.8% 2.14 1.30 61%
Q4/25*Dec 28, 2025 24.6B5.1B 20.8% – 1.30 –
Q3/25Sep 28, 2025 24.0B5.2B 21.5% 2.12 1.30 61%
Q2/25Jun 29, 2025 23.7B5.5B 23.3% 2.29 1.30 57%
Q1/25Mar 30, 2025 21.9B11.0B 50.2% 4.54 1.24 27%
Q4/24*Dec 29, 2024 22.5B3.4B 15.2% – 1.24 –
Q3/24Sep 29, 2024 22.5B2.7B 12.0% 1.11 1.24 112%
Q2/24Jun 30, 2024 22.4B4.7B 20.9% 1.93 1.24 64%
Q1/24Mar 31, 2024 21.4B3.3B 15.2% 1.34 1.19 89%
Q4/23Dec 31, 2023 21.4B4.0B 18.9% 1.67 1.19 71%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $62.0M4 people −$62.0M
6 months $00 people $70.2M6 people −$70.2M
12 months $257.7K1 person $150.7M10 people −$150.4M

Latest transactions

  • Sep 2, 2026 Schmid Timothy Officer Open-market sale 22,527 shares · $6.2M · SEC
  • Sep 2, 2026 Schmid Timothy Officer Open-market sale 11,070 shares · $3.0M · SEC
  • Aug 17, 2026 Taubert Jennifer L Officer Open-market sale 15,000 shares · $4.0M · SEC
  • Aug 13, 2026 Duato Joaquin Chief executive (CEO), Director Open-market sale 102,315 shares · $26.7M · SEC
  • Aug 13, 2026 Duato Joaquin Chief executive (CEO), Director Open-market sale 20,976 shares · $5.5M · SEC
  • Aug 6, 2026 Forminard Elizabeth Officer Open-market sale 6,574 shares · $1.7M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +55

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)16.2
Rel. strength 60 d+4.6%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on JNJ yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: JNJ

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close